This study found that nursing experience and level of education do not significantly affect the readiness of nurses to adopt a feeding protocol. Medical and nursing teams should not shy away from introducing a new protocol although their nurses have little experience or prior knowledge of that protocol. Future studies to investigate the impact of tailoring of educational needs before introduction of a new protocol are necessary to study the overall effectiveness of this teaching before introducing a new protocol in the ICU.
BackgroundParenteral nutrition (PN) is the mainstay of treatment in children with chronic intestinal failure. We review our experience in home parenteral nutrition and describe outcomes of long term home PN therapy.MethodsA retrospective cohort study was conducted by retrieving clinical records of patients with primary digestive diseases who were on home parenteral nutrition between July 2014 to July 2016.Results13 patients (4 boys, 9 girls) received PN for more than 2 months. Out of these, 8 patients required PN therapy for more than 6 months. Main indications for long-term PN included chronic intestinal pseudo-obstruction syndrome (CIPOS, 38%), short bowel syndrome (SBS, 54%) and inflammatory bowel disease (IBD, 8%). Median age for initiation of PN was 1.7 years. Median duration of PN therapy was 1.4 years. 6 patients (46%), all with SBS, were successfully weaned off PN.One of the major complications of long term PN was central line-associated bloodstream infection (CLABSI). Incidence of CLABSI was 5.3 per 1000 catheter days. After implementation of use of Taurolidine-citrate solution (TCS), a catheter-lock solution, incidence of CLABSI improved with a pre and post-TCS CLABSI rate ratio of 0.17 (95% CI 0.04–0.52, p<0.001). There was no biochemical evidence of intestinal failure associated liver disease (IFALD) in all patients. This may be, in part, related to our practice of using SMOF lipid for patients requiring more than 2 weeks of PN. Only 2 patients exhibited lower final BMI Z-scores of < −2. There was a 100% survival in this study group.ConclusionsPN is a safe and crucial modality of treatment in children with chronic intestinal failure. SBS forms the largest subgroup in our paediatric intestinal failure population. However, patients in this subgroup were also more likely to be weaned off PN. Incidence of CLABSI can be effectively controlled with introduction of TCS. Incidence of IFALD can also be reduced with SMOF and other new lipids.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.